Endonovo Therapeutics (ENDV) 10-Q 22 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Aug. 19, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	000-55453
Entity Registrant Name	ENDONOVO THERAPEUTICS, INC.
Entity Central Index Key	0001528172
Entity Tax Identification Number	45-2552528
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	6320 Canoga Avenue
Entity Address, Address Line Two	15th Floor
Entity Address, City or Town	Woodland Hills
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91367
City Area Code	(800)
Local Phone Number	489-4774
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		152,477,537

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash		$ 85,936
Accounts receivable, net of allowance for doubtful accounts of $0	945	944
Prepaid expenses and other current assets	5,000	7,975
Total current assets	5,945	94,855
Patents, net	1,588,900	1,912,356
Total assets	1,594,845	2,007,211
Current liabilities
Accounts payable and accrued liabilities	786,032	658,463
Accrued interest	3,032,796	2,528,459
Deferred compensation	4,210,261	3,891,361
Notes payable, net of discounts of $49,830 and $75,800 as of June 30, 2022, and December 31, 2021	7,237,204	7,055,030
Notes payable – former related party	119,600	126,100
Derivative liability	5,289,261	3,442,297
Total current liabilities	20,675,154	17,701,710
Acquisition payable	79,825	79,825
Total liabilities	20,754,979	17,781,535
COMMITMENTS AND CONTINGENCIES, note 9
Shareholders’ deficit
Preferred value
Common stock, $0.0001 par value; 2,500,000,000 shares authorized; 150,427,538 and 74,498,761 shares issued and outstanding as of June 30, 2022, and December 31, 2021	15,042	7,449
Additional paid-in capital	42,209,124	40,663,187
Stock subscriptions	(1,570)	(1,570)
Accumulated deficit	(61,382,756)	(56,443,416)
Total shareholders’ deficit	(19,160,134)	(15,774,324)
Total liabilities and shareholders’ deficit	1,594,845	2,007,211
Super AA Super Voting Preferred Stock [Member]
Shareholders’ deficit
Preferred value	25	25
Series B Convertible Preferred Stock [Member]
Shareholders’ deficit
Preferred value	1	1
Series C Convertible Preferred Stock [Member]
Shareholders’ deficit
Preferred value
Series D Convertible Preferred Stock [Member]
Shareholders’ deficit
Preferred value

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Allowance for doubtful accounts receivable	$ 0	$ 0
Discounts on notes payable current	$ 49,830	$ 75,800
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	2,500,000,000	2,500,000,000
Common stock, shares issued	150,427,538	74,498,761
Common stock, shares outstanding	150,427,538	74,498,761
Super AA Super Voting Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	25,000	25,000
Preferred stock, shares outstanding	25,000	25,000
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	50,000	50,000
Preferred stock, shares issued	600	600
Preferred stock, shares outstanding	600	600
Series C Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	8,000	8,000
Preferred stock, shares issued	738	738
Preferred stock, shares outstanding	738	738
Series D Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	20,000	20,000
Preferred stock, shares issued	305	305
Preferred stock, shares outstanding	305	305

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Revenue	$ 650	$ 30,284	$ 2,932	$ 64,999
Cost of revenue	383	500	1,097	3,021
Gross profit	267	29,784	1,835	61,978
Operating expenses	1,799,016	599,837	2,286,346	1,222,475
Loss from operations	(1,798,749)	(570,053)	(2,284,511)	(1,160,497)
Other income (expense)
Change in fair value of derivative liability	(316,606)	(720,439)	(1,846,964)	(2,420,449)
Gain on settlement of debt	104,760	114,021	43,813	70,996
Other expense	(178,000)		(178,000)
Interest expense, net	(337,536)	(120,198)	(673,678)	(467,600)
Other expense	(727,382)	(726,616)	(2,654,829)	(2,817,053)
Loss before income taxes	(2,526,131)	(1,296,669)	(4,939,340)	(3,977,550)
Provision for income taxes
Net Loss	$ (2,526,131)	$ (1,296,669)	$ (4,939,340)	$ (3,977,550)
Basic Loss per share	$ (0.02)	$ (0.02)	$ (0.05)	$ (0.08)
Diluted Loss per share	$ (0.02)	$ (0.02)	$ (0.05)	$ (0.08)
Weighted average common share outstanding:
Basic	134,360,871	58,487,227	106,696,127	50,084,150
Diluted	134,360,871	58,487,227	106,696,127	50,084,150

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities:
Net Loss	$ (4,939,340)	$ (3,977,550)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization expense	323,456	325,036
Stock compensation expense		40,961
Fair value of commitment shares issued with debt		33,470
Fair value of equity issued for services	1,281,900
Gain on extinguishment of debt	(43,813)	(70,996)
Amortization of note discount and original issue discount	59,138	72,751
Change in fair value of derivative liability	1,846,964	2,420,449
Changes in assets and liabilities:
Accounts receivable		(8,475)
Prepaid expenses and other current assets	2,975	11,100
Account payable & accrued liabilities	205,844	10,304
Accrued interest	614,540	361,379
Deferred compensation	318,900	355,689
Net cash used in operating activities	(329,436)	(425,882)
Financing activities:
Proceeds from the issuance of notes payable	250,000	325,000
Repayments on former related-party of notes payable	(6,500)	(22,000)
Repayments of convertible debt in cash		(8,000)
Proceeds from issuance of common stock and units		126,000
Net cash provided by financing activities	243,500	421,000
Net decrease in cash	(85,936)	(4,882)
Cash, beginning of year	85,936	13,420
Cash, end of period		8,538
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for income taxes
Non-Cash Investing and Financing Activities:
Conversion of notes payable and accrued interest to common stock	204,000	501,629
Conversion of Preferred C Stock to common stock		33,333
Debt discount from commitment shares issued with notes	$ 33,167

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Shareholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member] Series AA Preferred Stock [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Subscription Receivable [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 25	$ 1			$ 2,453	$ 38,963,827	$ (1,570)	$ (53,338,522)	$ (14,373,786)
Beginning balance, shares at Dec. 31, 2020	25,000	600	763	305	24,536,689
Shares issued for conversion of notes payable and accrued interest					$ 1,769	831,429			833,198
Shares issued for conversion of notes payable and accrued interest, shares					17,686,548
Net loss								(2,680,881)	(2,680,881)
Shares issued as commitment to note holders					$ 230	101,652			101,882
Shares issued as commitment to note holders, shares					2,300,334
Common stock issued for cash					$ 700	125,300			126,000
Common stock issued for cash, shares					7,000,000
Valuation of stock options issued for services						20,471			20,471
Ending balance, value at Mar. 31, 2021	$ 25	$ 1			$ 5,152	40,042,679	(1,570)	(56,019,403)	(15,973,116)
Ending balance, shares at Mar. 31, 2021	25,000	600	763	305	51,523,571
Beginning balance, value at Dec. 31, 2020	$ 25	$ 1			$ 2,453	38,963,827	(1,570)	(53,338,522)	(14,373,786)
Beginning balance, shares at Dec. 31, 2020	25,000	600	763	305	24,536,689
Net loss									(3,977,550)
Ending balance, value at Jun. 30, 2021	$ 25	$ 1			$ 6,067	40,327,526	(1,570)	57,316,072	(16,984,023)
Ending balance, shares at Jun. 30, 2021	25,000	600	738	305	60,659,771
Beginning balance, value at Mar. 31, 2021	$ 25	$ 1			$ 5,152	40,042,679	(1,570)	(56,019,403)	(15,973,116)
Beginning balance, shares at Mar. 31, 2021	25,000	600	763	305	51,523,571
Shares issued for conversion of notes payable and accrued interest					$ 381	116,165			116,546
Shares issued for conversion of notes payable and accrued interest, shares					3,804,103
Net loss								(1,296,669)	(1,296,669)
Shares issued as commitment to note holders					$ 20	6,280			6,300
Shares issued as commitment to note holders, shares					200,000
Valuation of stock options issued for services						20,491			20,491
Shares issued for conversion of Preferred Series C to Common share					$ 111	(111)
Shares issued for conversion of Preferred Series C to Common share, shares			(25)		1,111,111
Common Shares issued for debt settlement					$ 152	57,576			57,728
Shares issued as settlement of debt with former related party					$ 251	84,446			84,697
Shares issued as settlement of debt with former related party, shares					2,505,834
Ending balance, value at Jun. 30, 2021	$ 25	$ 1			$ 6,067	40,327,526	(1,570)	57,316,072	(16,984,023)
Ending balance, shares at Jun. 30, 2021	25,000	600	738	305	60,659,771
Beginning balance, value at Dec. 31, 2021	$ 25	$ 1			$ 7,449	40,663,187	(1,570)	(56,443,416)	(15,774,324)
Beginning balance, shares at Dec. 31, 2021	25,000	600	738	305	74,498,761
Shares issued for conversion of notes payable and accrued interest					$ 370	88,430			88,800
Shares issued for conversion of notes payable and accrued interest, shares					3,700,000
Common stock issued for settlement of debt					$ 243	45,904			46,147
Common stock issued for settlement of debt, shares					2,428,777
Issuance of commitment shares in connection with promissory note					$ 70	15,680			15,750
Issuance of commitment shares in connection with promissory note, shares					700,000
Net loss								(2,413,209)	(2,413,409)
Common Shares issued for debt settlement, shares					1,515,152
Ending balance, value at Mar. 31, 2022	$ 25	$ 1			$ 8,132	40,813,201	(1,570)	(58,856,625)	(18,036,836)
Ending balance, shares at Mar. 31, 2022	25,000	600	738	305	81,327,538
Beginning balance, value at Dec. 31, 2021	$ 25	$ 1			$ 7,449	40,663,187	(1,570)	(56,443,416)	(15,774,324)
Beginning balance, shares at Dec. 31, 2021	25,000	600	738	305	74,498,761
Net loss									(4,939,340)
Common Shares issued for services									$ 1,281,900
Common Shares issued for services, shares									62,250,000
Ending balance, value at Jun. 30, 2022	$ 25	$ 1			$ 15,042	42,209,124	(1,570)	61,382,756	$ (19,160,134)
Ending balance, shares at Jun. 30, 2022	25,000	600		305	150,427,538
Beginning balance, value at Mar. 31, 2022	$ 25	$ 1			$ 8,132	40,813,201	(1,570)	(58,856,625)	(18,036,836)
Beginning balance, shares at Mar. 31, 2022	25,000	600	738	305	81,327,538
Shares issued for conversion of notes payable and accrued interest					$ 650	114,550			115,200
Shares issued for conversion of notes payable and accrued interest, shares					6,500,000
Issuance of commitment shares in connection with promissory note					$ 35	5,698			5,733
Issuance of commitment shares in connection with promissory note, shares					350,000
Net loss								(2,526,131)	(2,526,131)
Common Shares issued for services					$ 6,225	1,275,675			1,281,900
Common Shares issued for services, shares					62,250,000
Ending balance, value at Jun. 30, 2022	$ 25	$ 1			$ 15,042	$ 42,209,124	$ (1,570)	$ 61,382,756	$ (19,160,134)
Ending balance, shares at Jun. 30, 2022	25,000	600		305	150,427,538

Organization and Nature of Busi

Organization and Nature of Business	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Business	Note 1 - Organization and Nature of Business Endonovo Therapeutics, Inc. (Endonovo or the “Company”) is an innovative biotechnology company that has developed a bio-electronic approach to regenerative medicine. Endonovo is a growth stage company whose stock is publicly traded (OTCQB: ENDV). The Company develops, manufactures, and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema, and inflammation in the human body. The Company’s non-invasive bioelectric medical devices are designed to target inflammation, cardiovascular diseases, chronic kidney disease, and central nervous system disorders (“CNS” disorders). The Company’s non-invasive Electroceutical® therapeutics device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative plain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceutical® therapeutics devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD) and ischemic stroke. Endonovo’s core mission is to transform the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver the Company’s Electroceutical ® ® bioelectricity

Summary of significant accounti

Summary of significant accounting policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of significant accounting policies	Note 2 – Summary of significant accounting policies Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of June 30, 2022, and 2021, are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 14, 2022. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year. Liquidity and Going Concern The Company’s unaudited condensed consolidated financial statements are prepared using GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to obtain adequate capital to fund operating losses until it becomes profitable. As of June 30, 2022, the Company had cash of $ 0 20.7 0.3 61.4 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) During the six months ended June 30, 2022, the Company has raised approximately $ 0.3 No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has commenced implementing its business plan to materialize revenues from potential future license agreements, and or diversifying its business activities with the potential acquisition of specialty construction company. The Company will continue to raise additional capital through the issuance of fixed-rate conversion feature promissory notes. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates. Earnings (Loss) Per Share The Company utilizes Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260, “Earnings per Share.” Basic earnings (loss) per share is computed based on the earnings (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted earnings (loss) per common share is calculated similar to basic earnings (loss) per share except that the denominator is increased to include additional common share equivalents available upon exercise of stock option, warrants, common shares issuable under convertible debt and restricted stock using the treasury stock method. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated based on the average share price for each period using the treasury stock method, excluding any common share equivalents if their effect would be anti-dilutive. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. Securities that are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been antidilutive for the three months ended June 30, 2022, include stock options, warrants, and notes payable. The Company has 513,730 2,000 3,013,730 28,309 Accounts Receivable The Company uses the specific identification method for recording the provision for doubtful accounts, which was $ 0 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) Newly Adopted Accounting Principles In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. In addition, ASU 2020-06 amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The Amendments also affects the diluted EPS calculation for instruments that may be settled in cash or shares and for convertible instruments. The amendments are effective for public entities excluding smaller reporting companies for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods. The Company adopted the new standard update on January 1, 2021, which did not result in a material impact on the Company’s condensed consolidated results of operations, financial position, and cash flows. The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s financial statements.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Note 3 - Revenue Recognition Contracts with Customers The Company adopted ASC 606, Revenue from Contracts with Customers . The Company routinely plan on entering into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products and services that we offer. The Company’s performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. The Company identified performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the customer’s contract and/or purchase order. The Company generally recognize revenue upon the satisfaction of these criteria when control of the product or service has been transferred to the customer at which time, the Company has an unconditional right to receive payment. The Company’s sales and sale prices are final, and our prices are not affected by contingent events that could impact the transaction price. Revenues for our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. In connection with offering products and services provided to the end user by third-party vendors, the Company reviews the relationship between us, the vendor, and the end user to assess whether revenue should be reported on a gross or net basis. In asserting whether revenue should be reported on a gross or net basis, the Company considers whether the Company acts as a principal in the transaction and control the goods and services used to fulfill the performance obligation(s) associated with the transaction. Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) Sources of Revenue The Company has identified the following revenues by revenue source: 1. Medical care providers For the three and six months ended June 30, 2022, and 2021, the sources of revenue were as follows: Schedule of Source of Revenue Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Direct sales- medical care providers, gross $ 650 $ 30,284 $ 2,932 $ 64,999 Total sources of revenue $ 650 $ 30,284 $ 2,932 $ 64,999 Warranty Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations. Significant Judgments in the Application of the Guidance in ASC 606 There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon shipment of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Performance obligations are also generally settled quickly after the purchase order acceptance, therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial. We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary. Practical Expedients Our payment terms for sales direct to distributors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists. Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued)

Patents

Patents	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	Note 4 – Patents In December 2017, we acquired from Rio Grande Neurosciences, Inc. (RGN) a patent portfolio for $ 4,500,000 2024 Schedule of Patents June 30, December 31, Patents $ 4,500,000 $ 4,500,000 Less accumulated amortization 2,911,100 2,587,644 Patents, net $ 1,588,900 $ 1,912,356 Amortization expense associated with patents was $ 323,456 The estimated future amortization expense related to patents as of June 30, 2022, is as follows: Schedule of Estimated Future Amortization Expense Twelve Months Ending June 30, Amount 2023 $ 646,910 2024 646,910 2025 295,080 Total $ 1,588,900

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Notes Payable	Note 5- Notes Payable Activity for the six months ended June 30, 2022 Fixed rates Notes During the six months ended June 30, 2022, the Company issued three (3) fixed rate promissory notes totaling $ 250,000 250,000 original terms of nine months and interest rates of 15 As of June 30, 2022, the Company has sixteen (16) fixed-rate promissory notes with an outstanding balance of $ 1,891,204 1,116,204 In October 2013, July 2014, October 2014 and August 2015, the Company initiated a series of private placements for up to $ 500,000 25,000 10 624,903 During the six months ended June 30, 2022, the Company converted $ 110,204 93,796 10,200,000 As of June 30, 2022, the Company has a total of sixteen (16) fixed-rate notes, of which twelve (12) for total principal amount of $ 1,250,000 15 178,000 Certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15 121,000 Variable-rate notes The gross amount of all convertible notes with variable conversion rates outstanding as of June 30, 2022, is $ 4,770,926 4,770,926 Activity for the six months ended June 30, 2021 During the six months ended June 30, 2021, the Company issued four (4) fixed rate promissory notes totaling $ 325,000 325,000 original terms of twelve months and interest rates of 15 During the six months ended June 30, 2021, the Company amended the terms of two of its promissory notes to accelerate the conversion feature and amend the conversion price of the instruments. The Company recorded the modification in accordance with ASC 470-50 Debt-Modifications and Extinguishments 58,407 During the six months ended June 30, 2021, the Company settled one of its promissory note by issuing 1,515,152 128,000 During the six months ended June 30, 2021, the Company paid $ 8,000 During the six months ended June 30, 2021, the Company converted $ 282,850 91,485 21,490,651 The gross amount of all convertible notes with variable conversion rates outstanding at June 30, 2021 is $ 4,770,926 2,660,476 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) Fixed Rate note (former related party) Notes payable to a former related party in the aggregate amount of $ 119,600 10 12 6,500 As of June 30, 2022, and December 31, 2021, the notes payable activity was as follows: Schedule of Notes Payable June 30, December 31, Notes payable at beginning of period $ 7,256,930 $ 6,835,196 Notes payable issued 250,000 950,000 Repayments of notes payable in cash (6,500 ) (16,900 ) Settlements on note payable - (117,770 ) Less amounts converted to stock (93,796 ) (393,596 ) Notes payable at end of period 7,406,634 7,256,930 Less debt discount (49,830 ) (75,800 ) $ 7,356,804 $ 7,181,730 Notes payable issued to a former related party $ 119,600 $ 126,100 Notes payable issued to non-related parties $ 7,237,204 $ 7,055,030 The maturity dates on the notes-payable are as follows: Schedule of Maturity Dates of Notes Payable Notes to 12 months ending, Former Related party Non-related parties Total Past due $ 119,600 $ 6,512,034 $ 6,631,634 June 30, 2022 - 775,000 775,000 $ 119,600 $ 7,287,034 $ 7,406,634 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued)

Shareholders_ Deficit

Shareholders’ Deficit	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Shareholders’ Deficit	Note 6 - Shareholders’ Deficit Preferred Stock The Company has authorized 5,000,000 Schedule of Preferred Stock Number of Shares Authorized Number of Shares Outstanding at June 30, 2022 Par Liquidation Series AA 1,000,000 25,000 $ 0.0010 $ - Preferred Series B 50,000 600 $ 0.0001 $ 100 Preferred Series C 8,000 738 $ 0.0001 $ 1,000 Preferred Series D 20,000 305 $ 0.0001 $ 1,000 Undesignated 3,922,000 - - - Series AA Preferred Shares On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million ( 1,000,000 0.001 Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company 25,000 Series B Convertible Preferred Stock On February 7, 2017, the Company filed a certificate of designation for 50,000 75 three-year 150 100 600 Series C Convertible Redeemable Preferred Stock On December 22, 2017, the Company filed a certificate of designation for 8,000 20.00 1,000 the Company filed the amended and restated certificate of designation fort its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The C Preferred does not have any rights to vote with the common stock Upon liquidation, the holder of Series C, shall be entitled to receive an amount equal to the stated value, $ 1,000 There was no activity during the six months ended June 30, 2022. As of June 30, 2022, there are 738 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) Series D Convertible Preferred Stock On November 11, 2019, the Company filed a certificate of designation for 20,000 0.01 The Series D holders have no voting rights. Upon liquidation, the holder of Series D, shall be entitled to receive an amount equal to the stated value, $ 1,000 305 Common Stock Activity during the six months ended June 30, 2022 During the six months ended June 30, 2022, the Company issued 10,200,000 93,796 110,204 During the six months ended June 30, 2022, the Company issued 2,428,777 During the six months ended June 30, 2022, the Company issued 1,050,000 During the six months ended June 30, 2022, the Company issued 62,250,000 1,281,900 Activity during the six months ended June 30, 2021 During the six months ended June 30, 2021, the Company issued 21,490,651 374,335 During the six months ended June 30, 2021, the Company issued 2,500,334 During the six months ended June 30, 2021, the Company issued 7,000,000 126,000 During the six months ended June 30, 2021, the Company issued 1,111,111 33,333 During the six months ended June 30, 2021, the Company issued 4,020,986 142,424 2,505,834 84,697 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) Stock Options The balance of all stock options outstanding as of June 30, 2022, is as follows: Schedule of Stock Options Outstanding Weighted Weighted Aggregate Exercise Price Contractual Intrinsic Options Per Share Term (years) Value Outstanding at January 1, 2022 513,730 $ 1.43 0.76 - Granted - $ - - - Cancelled - $ - - - Exercised - $ - - - Outstanding at June 30, 2022 513,730 $ 1.43 0.26 $ - Exercisable at June 30, 2022 513,730 $ 1.43 0.26 $ - Share-based compensation expense for the six months ended June 30, 2022, and 2021, totaled $ 0 40,961 Warrants The balance of all warrants outstanding as of June 30, 2022, is as follows: Schedule of Warrants Outstanding Outstanding Warrants Weighted Weighted Average Remaining Exercise Price Contractual Shares Per Share Term (years) Outstanding at January 1, 2022 22,200 $ 59.25 0.32 Granted - $ - - Cancelled (20,200 ) $ 60.17 - Exercised - $ - Outstanding at June 30, 2022 2,000 $ 50.00 0.72 Exercisable at June 30, 2022 2,000 $ 50.00 0.72 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued)

Related Party and former relate

Related Party and former related parties Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Related Party and former related parties Transactions	Note 7 – Related Party and former related parties Transactions One executive officer of the Company has agreed to defer a portion of his compensation until cash flow improves. As of June 30, 2022, the balance of the deferred compensation was $ 454,818 150,000 89,000 One former executive of the Company has agreed to defer a portion of his compensation until cash flow improves. As of June 30, 2022, the balance of his deferred compensation was $ 632,257 From time-to-time officer of the Company advance monies to the Company to cover costs. The balance of short-term advances due to one officer of the Company at June 30, 2022, was $ 925 5,662 4,862 As of June 30, 2022, notes payable remained outstanding to the former President of the Company, in the amount of $ 119,600 74,180

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 8 – Fair Value Measurements The Company has issued Variable Debentures which contained variable conversion rates based on unknown future prices of the Company’s common stock. This results in a conversion feature. The Company measures the conversion feature using the Black Scholes option pricing model using the following assumptions: Schedule of Conversion Feature Using Black Scholes Option Pricing Model Six months ended June 30, 2022 2021 Expected term 1 months 1 4 months Exercise price $ 0.004 0.015 $ 0.012 0.028 Expected volatility 153 169 182 206 Expected dividends None None Risk-free interest rate 1.63 2.80 0.07 0.13 Forfeitures None None The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment, or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future. The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases. Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the six months ended June 30, 2022: Schedule of Fair Value of Derivative Liability Derivative Liability Balance December 31, 2021 $ 3,442,297 Extinguishment - Change in estimated fair value 1,846,964 Balance June 30, 2022 $ 5,289,261 Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business. The Company’s balance sheet contains derivative liabilities that are recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows: Level 1: uses quoted market prices in active markets for identical assets or liabilities. Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: uses unobservable inputs that are not corroborated by market data. The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black Scholes option pricing model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation. The following table presents balances in the liabilities with significant unobservable inputs (Level 3) as of June 30, 2022: Schedule of Liabilities Significant Unobservable Inputs Fair Value Measurements Using Quoted Active Significant Other Significant Identical Observable Unobservable (Level 1) (Level 2) (Level 3) Total As of June 30, 2022 Derivative liability $ - $ - $ 5,289,261 $ 5,289,261 Total $ - $ - $ 5,289,261 $ 5,289,261

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9 – Commitments and Contingencies Legal Matters We were defendants in a case entitled Auctus Fund, LLC v. Endonovo Therapeutics, Inc. et.al 20-cv-11286-PBS 275,250 500,000 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) The Company is subject to certain legal proceedings, which it considers routine to its business activities. As of June 30, 2022, the Company believes, after consultation with legal counsel, that the ultimate outcome of such legal proceedings, whether individually or in the aggregate, is not likely to have a material adverse effect on the Company’s financial position, results of operations or liquidity.

Concentrations

Concentrations	6 Months Ended
	Jun. 30, 2022
Risks and Uncertainties [Abstract]
Concentrations	Note 10 – Concentrations Sales During the six months ended June 30, 2022, we had two significant customers, which accounted for approximately 72 Supplier We also have a single source for our bioelectric medical devices, which account for 100 Accounts Receivable At June 30, 2022, we had two customers which accounted for approximately 100

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 11 – Subsequent Events Management has evaluated events that have occurred subsequent to the date of these consolidated condensed financial statements and has determined that, other than those listed below, no such reportable subsequent events exist through the date the financial statements were issued in accordance with FASB ASC Topic 855, “Subsequent Events.” Subsequent to June 30, 2022, the Company entered into convertible fixed-rate promissory notes for a total amount of $ 150,000 Subsequent to June 30, 2022, the Company issued 2,050,000 Subsequent to June 30, 2022, pursuant to a settlement agreement between the parties the claims and counterclaims in the litigation have been dismissed without prejudice and the note is no longer outstanding with Auctus Fund LLC.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of June 30, 2022, and 2021, are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 14, 2022. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year.
Liquidity and Going Concern	Liquidity and Going Concern The Company’s unaudited condensed consolidated financial statements are prepared using GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to obtain adequate capital to fund operating losses until it becomes profitable. As of June 30, 2022, the Company had cash of $ 0 20.7 0.3 61.4 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) During the six months ended June 30, 2022, the Company has raised approximately $ 0.3 No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has commenced implementing its business plan to materialize revenues from potential future license agreements, and or diversifying its business activities with the potential acquisition of specialty construction company. The Company will continue to raise additional capital through the issuance of fixed-rate conversion feature promissory notes.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.
Earnings (Loss) Per Share	Earnings (Loss) Per Share The Company utilizes Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260, “Earnings per Share.” Basic earnings (loss) per share is computed based on the earnings (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted earnings (loss) per common share is calculated similar to basic earnings (loss) per share except that the denominator is increased to include additional common share equivalents available upon exercise of stock option, warrants, common shares issuable under convertible debt and restricted stock using the treasury stock method. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated based on the average share price for each period using the treasury stock method, excluding any common share equivalents if their effect would be anti-dilutive. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. Securities that are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been antidilutive for the three months ended June 30, 2022, include stock options, warrants, and notes payable. The Company has 513,730 2,000 3,013,730 28,309
Accounts Receivable	Accounts Receivable The Company uses the specific identification method for recording the provision for doubtful accounts, which was $ 0 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued)
Newly Adopted Accounting Principles	Newly Adopted Accounting Principles In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. In addition, ASU 2020-06 amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The Amendments also affects the diluted EPS calculation for instruments that may be settled in cash or shares and for convertible instruments. The amendments are effective for public entities excluding smaller reporting companies for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods. The Company adopted the new standard update on January 1, 2021, which did not result in a material impact on the Company’s condensed consolidated results of operations, financial position, and cash flows. The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s financial statements.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Source of Revenue	For the three and six months ended June 30, 2022, and 2021, the sources of revenue were as follows: Schedule of Source of Revenue Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Direct sales- medical care providers, gross $ 650 $ 30,284 $ 2,932 $ 64,999 Total sources of revenue $ 650 $ 30,284 $ 2,932 $ 64,999

Patents (Tables)

Patents (Tables)	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Patents	Schedule of Patents June 30, December 31, Patents $ 4,500,000 $ 4,500,000 Less accumulated amortization 2,911,100 2,587,644 Patents, net $ 1,588,900 $ 1,912,356
Schedule of Estimated Future Amortization Expense	The estimated future amortization expense related to patents as of June 30, 2022, is as follows: Schedule of Estimated Future Amortization Expense Twelve Months Ending June 30, Amount 2023 $ 646,910 2024 646,910 2025 295,080 Total $ 1,588,900

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of Notes Payable	As of June 30, 2022, and December 31, 2021, the notes payable activity was as follows: Schedule of Notes Payable June 30, December 31, Notes payable at beginning of period $ 7,256,930 $ 6,835,196 Notes payable issued 250,000 950,000 Repayments of notes payable in cash (6,500 ) (16,900 ) Settlements on note payable - (117,770 ) Less amounts converted to stock (93,796 ) (393,596 ) Notes payable at end of period 7,406,634 7,256,930 Less debt discount (49,830 ) (75,800 ) $ 7,356,804 $ 7,181,730 Notes payable issued to a former related party $ 119,600 $ 126,100 Notes payable issued to non-related parties $ 7,237,204 $ 7,055,030
Schedule of Maturity Dates of Notes Payable	The maturity dates on the notes-payable are as follows: Schedule of Maturity Dates of Notes Payable Notes to 12 months ending, Former Related party Non-related parties Total Past due $ 119,600 $ 6,512,034 $ 6,631,634 June 30, 2022 - 775,000 775,000 $ 119,600 $ 7,287,034 $ 7,406,634

Shareholders_ Deficit (Tables)

Shareholders’ Deficit (Tables)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Schedule of Preferred Stock	Schedule of Preferred Stock Number of Shares Authorized Number of Shares Outstanding at June 30, 2022 Par Liquidation Series AA 1,000,000 25,000 $ 0.0010 $ - Preferred Series B 50,000 600 $ 0.0001 $ 100 Preferred Series C 8,000 738 $ 0.0001 $ 1,000 Preferred Series D 20,000 305 $ 0.0001 $ 1,000 Undesignated 3,922,000 - - -
Schedule of Stock Options Outstanding	The balance of all stock options outstanding as of June 30, 2022, is as follows: Schedule of Stock Options Outstanding Weighted Weighted Aggregate Exercise Price Contractual Intrinsic Options Per Share Term (years) Value Outstanding at January 1, 2022 513,730 $ 1.43 0.76 - Granted - $ - - - Cancelled - $ - - - Exercised - $ - - - Outstanding at June 30, 2022 513,730 $ 1.43 0.26 $ - Exercisable at June 30, 2022 513,730 $ 1.43 0.26 $ -
Schedule of Warrants Outstanding	The balance of all warrants outstanding as of June 30, 2022, is as follows: Schedule of Warrants Outstanding Outstanding Warrants Weighted Weighted Average Remaining Exercise Price Contractual Shares Per Share Term (years) Outstanding at January 1, 2022 22,200 $ 59.25 0.32 Granted - $ - - Cancelled (20,200 ) $ 60.17 - Exercised - $ - Outstanding at June 30, 2022 2,000 $ 50.00 0.72 Exercisable at June 30, 2022 2,000 $ 50.00 0.72

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Conversion Feature Using Black Scholes Option Pricing Model	Schedule of Conversion Feature Using Black Scholes Option Pricing Model Six months ended June 30, 2022 2021 Expected term 1 months 1 4 months Exercise price $ 0.004 0.015 $ 0.012 0.028 Expected volatility 153 169 182 206 Expected dividends None None Risk-free interest rate 1.63 2.80 0.07 0.13 Forfeitures None None
Schedule of Fair Value of Derivative Liability	The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the six months ended June 30, 2022: Schedule of Fair Value of Derivative Liability Derivative Liability Balance December 31, 2021 $ 3,442,297 Extinguishment - Change in estimated fair value 1,846,964 Balance June 30, 2022 $ 5,289,261
Schedule of Liabilities Significant Unobservable Inputs	The following table presents balances in the liabilities with significant unobservable inputs (Level 3) as of June 30, 2022: Schedule of Liabilities Significant Unobservable Inputs Fair Value Measurements Using Quoted Active Significant Other Significant Identical Observable Unobservable (Level 1) (Level 2) (Level 3) Total As of June 30, 2022 Derivative liability $ - $ - $ 5,289,261 $ 5,289,261 Total $ - $ - $ 5,289,261 $ 5,289,261

Summary of significant accoun_3

Summary of significant accounting policies (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Cash	$ 0
Working capital	20,700,000
Net Cash Provided by (Used in) Operating Activities	329,436	$ 425,882
Accumulated deficit	61,382,756		$ 56,443,416
Proceeds from debt and equity financing	300,000
Accounts Receivable, Allowance for Credit Loss, Current	$ 0		$ 0
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive shares	513,730	3,013,730
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive shares	2,000	28,309

Schedule of Source of Revenue (

Schedule of Source of Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Total sources of revenue	$ 650	$ 30,284	$ 2,932	$ 64,999
Direct Sales- Medical Care Providers [Member]
Disaggregation of Revenue [Line Items]
Total sources of revenue	$ 650	$ 30,284	$ 2,932	$ 64,999

Schedule of Patents (Details)

Schedule of Patents (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 4,500,000	$ 4,500,000
Less accumulated amortization	2,911,100	2,587,644
Patents, net	$ 1,588,900	$ 1,912,356

Schedule of Estimated Future Am

Schedule of Estimated Future Amortization Expense (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 646,910
2024	646,910
2025	295,080
Patents, net	$ 1,588,900	$ 1,912,356

Patents (Details Narrative)

Patents (Details Narrative) - USD ($)	1 Months Ended	6 Months Ended
	Dec. 31, 2017	Jun. 30, 2022	Jun. 30, 2021
Amortization expense		$ 323,456	$ 323,456
Rio Grande Neurosciences, Inc. [Member]
Acquisition of patents	$ 4,500,000
Patents expiration period	2024

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Notes payable at beginning of period	$ 7,256,930	$ 6,835,196
Notes payable issued	250,000	950,000
Repayments of notes payable in cash	(6,500)	(16,900)
Settlements on note payable		(117,770)
Less amounts converted to stock	(93,796)	(393,596)
Notes payable at end of period	7,406,634	7,256,930
Less debt discount	(49,830)	(75,800)
Note payable, net	7,356,804	7,181,730
Notes payable issued to a former related party	119,600	126,100
Notes payable issued to non-related parties	$ 7,237,204	$ 7,055,030

Schedule of Maturity Dates of N

Schedule of Maturity Dates of Notes Payable (Details)	Jun. 30, 2022 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Past due	$ 6,631,634
June 30, 2022	775,000
Total	7,406,634
Former Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Past due	119,600
June 30, 2022
Total	119,600
Non Related Parties [Member]
Defined Benefit Plan Disclosure [Line Items]
Past due	6,512,034
June 30, 2022	775,000
Total	$ 7,287,034

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Aug. 31, 2015	Oct. 31, 2014	Jul. 31, 2014	Oct. 31, 2013
Short-Term Debt [Line Items]
Note payable	$ 7,406,634		$ 7,406,634		$ 7,256,930	$ 6,835,196
Proceeds from Notes Payable			$ 250,000	$ 325,000
Debt instrument, interest rate							10%	10%	10%	10%
Percentage of cash premium			15%
Prepayment penalty	121,000		$ 121,000
Gain on debt extinguishment	104,760	$ 114,021	43,813	70,996
Note payable related parties	119,600		119,600		126,100
Gain (Loss) on Derivative Instruments [Member]
Short-Term Debt [Line Items]
Gain on debt extinguishment				58,407
Private Placement [Member]
Short-Term Debt [Line Items]
Note payable	624,903		624,903		$ 624,903
Maximum [Member] | Private Placement [Member]
Short-Term Debt [Line Items]
Note payable							$ 500,000	$ 500,000	$ 500,000	$ 500,000
Minimum [Member] | Private Placement [Member]
Short-Term Debt [Line Items]
Note payable							$ 25,000	$ 25,000	$ 25,000	$ 25,000
One Promissory Notes [Member]
Short-Term Debt [Line Items]
Note payable	$ 250,000		250,000
Proceeds from Notes Payable			$ 250,000
Debt instrument description			original terms of nine months and interest rates of 15%. The holder of the promissory note can convert the outstanding unpaid principal and accrued interest at a fixed conversion rate, subject to standard anti-dilution features, six-month after issuance date
Debt instrument, interest rate	15%		15%
Fixed Rated Notes [Member]
Short-Term Debt [Line Items]
Note payable	$ 1,891,204		$ 1,891,204
Debt conversion, value			110,204
Accrued interest	93,796		$ 93,796
Debt conversion, stock issued			10,200,000
Fixed Rated Notes [Member] | Past Maturity [Member]
Short-Term Debt [Line Items]
Note payable	1,116,204		$ 1,116,204
Sixteen Fixed Rate [Member]
Short-Term Debt [Line Items]
Accrued interest	178,000		178,000
Debt instrument, face amount	1,250,000		$ 1,250,000
Profit reselling conversion shares rate			15%
Convertible Notes [Member]
Short-Term Debt [Line Items]
Convertible Debt	4,770,926		$ 4,770,926
Convertible Notes [Member] | Past Maturity [Member]
Short-Term Debt [Line Items]
Convertible Debt	4,770,926		4,770,926
Four Fixed Promissory Notes [Member]
Short-Term Debt [Line Items]
Note payable		$ 325,000		325,000
Proceeds from Notes Payable				$ 325,000
Debt instrument description				original terms of twelve months and interest rates of 15%. The holders of the promissory notes can convert the outstanding unpaid principal and accrued interest at a fixed conversion rate, subject to standard anti-dilution features
Debt instrument, interest rate		15%		15%
Promissory Notes [Member]
Short-Term Debt [Line Items]
Note payable		$ 1,515,152		$ 1,515,152
Debt conversion, value				282,850
Accrued interest		91,485		91,485
Gain on debt extinguishment				128,000
Principal payment of debt				$ 8,000
Debt conversion, stock issued				21,490,651
Convertible Debentures One [Member]
Short-Term Debt [Line Items]
Convertible Debt		4,770,926		$ 4,770,926
Convertible Debentures One [Member] | Past Maturity [Member]
Short-Term Debt [Line Items]
Convertible Debt		$ 2,660,476		$ 2,660,476
Notes Payable [Member] | Former Related Party [Member]
Short-Term Debt [Line Items]
Principal payment of debt			6,500
Note payable related parties	$ 119,600		$ 119,600
Notes Payable [Member] | Maximum [Member] | Former Related Party [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate	12%		12%
Notes Payable [Member] | Minimum [Member] | Former Related Party [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate	10%		10%

Schedule of Preferred Stock (De

Schedule of Preferred Stock (Details)	Jun. 30, 2022 USD ($) $ / shares shares
Series AA [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized	1,000,000
Number of shares outstanding	25,000
Par value | $ / shares	$ 0.0010
Liquidation value | $
Preferred Series B [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized	50,000
Number of shares outstanding	600
Par value | $ / shares	$ 0.0001
Liquidation value | $	$ 100
Preferred Series C [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized	8,000
Number of shares outstanding	738
Par value | $ / shares	$ 0.0001
Liquidation value | $	$ 1,000
Preferred Series D [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized	20,000
Number of shares outstanding	305
Par value | $ / shares	$ 0.0001
Liquidation value | $	$ 1,000
Undesignated [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized	3,922,000
Number of shares outstanding
Par value | $ / shares
Liquidation value | $

Schedule of Stock Options Outst

Schedule of Stock Options Outstanding (Details) - Equity Option [Member]	6 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Stock Option Outstanding, Beginning Balance | shares	513,730
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 1.43
Weighted Average Remaining Contractual Term (years), Outstanding Beginning	9 months 3 days
Aggregated Intrinsic Value, Outstanding Beginning Balance | $
Stock Option Outstanding, Granted | shares
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Remaining Contractual Term (years), Granted
Aggregated Intrinsic Value, Outstanding, Granted | $
Stock Option Outstanding, Cancelled | shares
Weighted Average Exercise Price, Cancelled | $ / shares
Weighted Average Remaining Contractual Term (years), Cancelled
Aggregated Intrinsic Value, Outstanding, Cancelled | $
Stock Option Outstanding, Exercised | shares
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Remaining Contractual Term (years), Exercised
Aggregated Intrinsic Value, Outstanding, Exercised | $
Stock Option Outstanding, Ending Balance | shares	513,730
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 1.43
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	3 months 3 days
Aggregated Intrinsic Value, Outstanding Ending | $
Stock Option Outstanding, Exercisable Ending Balance | shares	513,730
Weighted Average Exercise Price, Exercisable Ending Balance | $ / shares	$ 1.43
Weighted Average Remaining Contractual Term (years), Exercisable	3 months 3 days
Aggregated Intrinsic Value, Exercisable Ending | $

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding (Details) - Warrant [Member]	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares Outstanding, Beginning Balance | shares	22,200
Weighted-Average Exercise Price, Outstanding Beginning Balance | $ / shares	$ 59.25
Weighted Average Remaining Contractual Term (years), Outstanding Beginning	3 months 25 days
Shares, Granted | shares
Weighted-Average Exercise Price, Granted | $ / shares
Shares, Cancelled | shares	(20,200)
Weighted average Exercise price, Cancelled | $ / shares	$ 60.17
Shares, Exercised | shares
Weighted-Average Exercise Price, Exercised | $ / shares
Shares Outstanding, Ending Balance | shares	2,000
Weighted-Average Exercise Price, Outstanding Ending Balance | $ / shares	$ 50
Weighted Average Remaining Contractual Term (years), Outstanding Ending	8 months 19 days
Shares Exercisable, Ending Balance | shares	2,000
Weighted-Average Exercise Price, Exercisable Ending Balance | $ / shares	$ 50
Weighted Average Remaining Contractual Term (years), Exercisable Ending	8 months 19 days

Shareholders_ Deficit (Details

Shareholders’ Deficit (Details Narrative) - USD ($)					3 Months Ended		6 Months Ended
	Jan. 29, 2020	Dec. 22, 2017	Feb. 07, 2017	Feb. 22, 2013	Jun. 30, 2022	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Nov. 11, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock Issued During Period, Shares, Issued for Services							62,250,000
Stock Issued During Period, Value, Issued for Services					$ 1,281,900		$ 1,281,900
Stock Issued During Period, Value, New Issues						$ 126,000
Share-based compensation expenses								$ 40,961
Former Related Party [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock								2,505,834
Stock Issued During Period, Value, New Issues								$ 84,697
Promissory Notes [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accrued interest								$ 91,485
Issuance of common stock								2,500,334
Settlement of Debt [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock								4,020,986
Stock Issued During Period, Value, New Issues								$ 142,424
Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock							1,050,000	7,000,000
Stock Issued During Period, Value, New Issues								$ 126,000
One Investor [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock							2,428,777
Series AA Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares outstanding				1,000,000
Preferred stock, par value				$ 0.001
Preferred stock voting rights				Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company
Preferred stock, shares outstanding					25,000		25,000
Series B Convertible Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares outstanding			50,000		50,000		50,000		50,000
Preferred stock, par value					$ 0.0001		$ 0.0001		$ 0.0001
Preferred stock, shares outstanding					600		600		600
Stated value dividend			75%
Warrants term			three-year
Share exercise price			150%
Liquidation value of preferred stock, per share			$ 100
Series C Convertible Redeemable Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares outstanding		8,000
Preferred stock, shares outstanding					738		738
Liquidation value of preferred stock, per share		$ 1,000			$ 1,000		$ 1,000
Preferred stock, dividend per share		$ 20
Change in rights due to amendment and restated certificate, description	the Company filed the amended and restated certificate of designation fort its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The C Preferred does not have any rights to vote with the common stock
Series D Convertible Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares outstanding					20,000		20,000		20,000	20,000
Preferred stock, par value					$ 0.0001		$ 0.0001		$ 0.0001
Preferred stock, shares outstanding					305		305		305
Liquidation value of preferred stock, per share					$ 1,000		$ 1,000
Conversion price										0.01%
Preferred Stock Designated [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares outstanding					5,000,000		5,000,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares issued for conversion of notes payable, shares							10,200,000	21,490,651
Shares issued for conversion of notes payable							$ 93,796	$ 374,335
Accrued interest					$ 110,204		$ 110,204
Issuance of common stock						7,000,000
Stock Issued During Period, Shares, Issued for Services					62,250,000
Stock Issued During Period, Value, Issued for Services					$ 6,225
Stock Issued During Period, Value, New Issues						$ 700
Conversion Of Series C Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock								1,111,111
Stock Issued During Period, Value, New Issues								$ 33,333

Related Party and former rela_2

Related Party and former related parties Transactions (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Repayment of debt	$ 6,500	$ 22,000
Notes Payable, Related Parties, Current	119,600		$ 126,100
Interest Payable, Current	3,032,796		$ 2,528,459
Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Deferred compensation	454,818
Accrual deferred compensation	150,000
Cash repayments of deferred compensation	89,000
Advance from officer	5,662
Repayment of debt	4,862
One Former Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Deferred compensation	632,257
Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Due to officer	925
Former President [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Notes Payable, Related Parties, Current	119,600
Interest Payable, Current	$ 74,180

Schedule of Conversion Feature

Schedule of Conversion Feature Using Black Scholes Option Pricing Model (Details)	6 Months Ended
	Jun. 30, 2022 $ / shares	Jun. 30, 2021 $ / shares
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, term	1 month
Measurement Input, Expected Term [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, term		1 month
Measurement Input, Expected Term [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, term		4 months
Measurement Input, Exercise Price [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	0.004	0.012
Measurement Input, Exercise Price [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	0.015	0.028
Measurement Input, Price Volatility [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	1.53	1.82
Measurement Input, Price Volatility [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	1.69	2.06
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	0	0
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	0.0163	0.0007
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	0.0280	0.0013
Forfeitures [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	0	0

Schedule of Fair Value of Deriv

Schedule of Fair Value of Derivative Liability (Details) - Fair Value, Inputs, Level 3 [Member]	6 Months Ended
	Jun. 30, 2022 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, beginning	$ 3,442,297
Extinguishment
Change in estimated fair value	1,846,964
Derivative Liability, ending	$ 5,289,261

Schedule of Liabilities Signifi

Schedule of Liabilities Significant Unobservable Inputs (Details)	Jun. 30, 2022 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 5,289,261
Total	5,289,261
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability
Total
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability
Total
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	5,289,261
Total	$ 5,289,261

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - Auctus Fund, LLC [Member]	1 Months Ended
	Aug. 31, 2019 USD ($)
Other Unspecified Damages And Attorney Fees [Member]
Loss Contingencies [Line Items]
Loss Contingency, Damages Sought, Value	$ 500,000
Note [Member]
Loss Contingencies [Line Items]
Loss Contingency, Damages Sought, Value	$ 275,250

Concentrations (Details Narrati

Concentrations (Details Narrative)	6 Months Ended
	Jun. 30, 2022
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Two Significant Customers [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	72%
Revenue Benchmark [Member] | Supplier Concentration Risk [Member] | Supplier [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	100%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Two Customers [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	100%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member]	2 Months Ended
	Aug. 16, 2022 USD ($) shares
Subsequent Event [Line Items]
Convertible promissory note | $	$ 150,000
Investor [Member]
Subsequent Event [Line Items]
Issuance of common stock | shares	2,050,000